Navigation Links
Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response
Date:11/30/2009

NEW YORK, Nov. 30 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response

http://www.reportlinker.com/p0165600/Inflammatory-Disorders-Therapies-That-Suppress-or-Balance-the-Immune-Response.html

The human immune system can go awry, either attacking an individual body or producing an exaggerated response to a foreign substance that is normally benign. In these situations, immunotherapies are needed to balance or suppress the unwarranted immune response. In this report:

  • Approximately 400 product candidates and development programs are identified.
  • Current and emerging therapies for selected autoimmune or inflammatory disorders and prevention of organ transplant rejection, directed against a wide range of putative targets, are summarized.
  • Specifically, more than 250 emerging autoimmune disease therapies, 80 asthma therapies in development, and 50+ therapy candidates for allergies are covered.
  • The strategic consequences of intense competition in a crowded product space are considered.

Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response reviews the problems of insufficient efficacy, side effects, and adverse events associated with the small-molecule and biological drugs available today to treat these disorders. These observations have led to an interest in identifying ways to balance the immune reaction, to suppress the part of the immune response that is causing the disease, while maintaining or enhancing other aspects of the immune system. This report identifies nearly 400 ongoing product candidates and development programs in these indication areas. The companies active in these areas range from multinational pharmaceutical companies with a number of active programs to small boutique start-ups working on a very defined topic.

CHAPTER 1: INTRODUCTION

1.1. The Immune System

1.2. Scope of the Report

CHAPTER 2: REVIEW OF MAJOR DISEASES/ CONDITIONS TARGETED BY NEW AND/OR EMERGING IMMUNOTHERAPIES AND VACCINES TO SUPPRESS OR BALANCE THE IMMUNE SYSTEM

2.1. Major Autoimmune Diseases

Rheumatoid Arthritis

Type 1 Diabetes Mellitus

Inflammatory Bowel Disease--Crohn's Disease and Ulcerative Colitis

Multiple Sclerosis

Psoriasis

Psoriatic Arthritis

Systemic Lupus Erythematosus

2.2. Asthma

2.3. Allergies

2.4. Immune Suppression to Prevent

Rejection of Organ Transplants

CHAPTER 3: CURRENT PHARMACOLOGICAL TREATMENT OPTIONS

3.1. Major Autoimmune Diseases

Rheumatoid Arthritis

Nonsteroidal Anti-inflammatory Drugs

(NSAIDs)

Disease-Modifying Antirheumatic

Drugs (DMARDs)

Corticosteroids

Biological Response Modifiers

Type 1 Diabetes Mellitus

Inflammatory Bowel Disease--Crohn's Disease and Ulcerative Colitis

Multiple Sclerosis

Interferon-beta

Copaxone (glatiramer acetate)

Novantrone (mitoxantrone)

Tysabri (natalizumab)

Psoriasis

Psoriatic Arthritis

Systemic Lupus Erythematosus

3.2. Asthma

3.3. Allergies

3.4. Immune Suppression to Prevent Rejection of Organ Transplants

CHAPTER 4: CURRENT AND EMERGING APPROACHES TO SUPPRESS OR BALANCE THE IMMUNE SYSTEM FOR PREVENTION AND TREATMENT OF DISEASE

CHAPTER 5: EMERGING THERAPIES IN DEVELOPMENT FOR TREATMENT OF MAJOR AUTOIMMUNE DISEASES

5.1. Introduction

5.2. Abbott Laboratories

5.3. Biogen Idec

5.4. AstraZeneca

5.5. Bristol-Myers Squibb

5.6. Centocor Ortho Biotech

5.7. Centocor Ortho Biotech and Schering-Plough

5.8. Diamyd Medical

5.9. Eli Lilly and BioMS Medical

5.10. Eli Lilly and MacroGenics

5.11. Genzyme and Bayer

5.12. GlaxoSmithKline and Genmab

5.13. GlaxoSmithKline and Human Genome Sciences

5.14. GlaxoSmithKline and Tolerx

5.15. GlaxoSmithKline (Selected Additional Product Candidates and Research)

5.16. Isotechnika

5.17. Merck Serono and ZymoGenetics

5.18. Merck Serono

5.19. Novartis

Multiple Sclerosis

Rheumatoid Arthritis

Psoriasis

5.20. Pfizer

5.21. Roche and Chugai Pharmaceutical

5.22. Roche and Genentech (A Wholly-Owned Member of the Roche Group)

5.23. Sanofi-Aventis

5.24. Takeda Pharmaceutical and Millennium Pharmaceuticals

5.25. Teva Pharmaceutical Industries and Active Biotech

5.26. UCB

CHAPTER 6: EMERGING THERAPIES FOR TREATMENT OF ASTHMA

6.1. Pipeline Overview

6.2. Abbott Laboratories and SkyePharma (Also Mundipharma and Kyorin)

6.3. Aerovance

6.4. Amgen

6.5. AstraZeneca

6.6. Ception Therapeutics

6.7. Genentech

6.8. GlaxoSmithKline

6.9. Icagen

6.10. MediciNova

6.11. Pfizer

6.12. Schering-Plough and Novartis

6.13. Topigen Pharmaceuticals

6.14. Wyeth

CHAPTER 7: SELECTED EXAMPLES OF EMERGING THERAPIES FOR TREATMENT OF ALLERGIES

7.1. Introduction

7.2. ALK-Abello and Schering-Plough

7.3. Allergy Therapeutics

7.4. Ception Therapeutics

7.5. Cytos Biotechnology

7.6. Greer Laboratories

7.7. Stallergenes

CHAPTER 8: IMMUNOTHERAPIES IN DEVELOPMENT FOR PREVENTING REJECTION OF ORGAN TRANSPLANTS

8.1. Introduction

8.2. APT Pharmaceuticals

8.3. Astellas Pharma

8.4. Bristol-Myers Squibb

8.5. Isotechnika

8.6. Novartis

8.7. Pfizer

CHAPTER 9: BUSINESS CONSIDERATIONS --THERAPIES THAT SUPPRESS OR BALANCE THE IMMUNE SYSTEM

9.1. Current Market and Market Potential

9.2. Competition

9.3. Strong Interest on the Part of Major Pharmaceutical Companies

9.4. Agreements and Mergers/Acquisitions

9.5. Other Major Challenges and Hurdles Being Faced by Companies

Competition

Potential Need for Personalized Medicine in at Least Certain Situations

Targeted Patient Populations

CHAPTER 10: THOUGHT LEADER INTERVIEWS

10.1. David W. Pritchard, President and Chief Executive Officer, KaloBios

10.2. Randall C. Schatzman, PhD, President and Chief Executive Officer, Alder Biopharmaceuticals

10.3. Louis Vaickus, MD, Chief Medical Officer, Tolerx

10.4. Eric H. Zanelli, PhD, Vice President, Research, Peptimmune

REFERENCES

COMPANY INDEX WITH WEB ADDRESSES

To order this report:

Therapy Industry: Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response

More Market Research Report


Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015
2. Reportlinker Adds Mammography Equipment - A Global Market Perspective
3. Reportlinker Adds Pain Management - Global Trends
4. Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis
5. Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015
6. Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015
7. Reportlinker Adds U.S. Market for PACS and EMR
8. Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective
9. Reportlinker Adds Holter Monitoring Systems - A Global Market Review
10. Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review
11. Reportlinker Adds Anesthesia Disposables - A World Market Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... Centers for Disease Control and Prevention (CDC), influenza vaccination should take ... communities across Massachusetts , Connecticut , ... through the end of the month. *Some exclusions apply ... ... by the end of October, according to the Centers for Disease Control ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
Breaking Medicine Technology:
(Date:10/13/2017)... Ill. (PRWEB) , ... October ... ... Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer ... healthcare professionals on guideline updates for the primary prevention of cardiovascular diseases ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
Breaking Medicine News(10 mins):